Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes
10.1056/nejmc2036175
Saved in:
Main Authors: | George L. Bakris, Rajiv Agarwal, Stefan D. Anker, Bertram Pitt, Luis M. Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph, Gerasimos Filippatos, for the FIDELIO-DKD Investigators |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
Massachusetts Medical Society
2022
|
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/229778 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
by: Pitt, Bertram, et al.
Published: (2023) -
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
by: Bakris, George L, et al.
Published: (2023) -
Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
by: Filippatos, Gerasimos, et al.
Published: (2022) -
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
by: Anantharaman, Vathsala, et al.
Published: (2023) -
Riboregulators in kidney development and function
by: Karolina, D.S., et al.
Published: (2011)